On Par: completion of $410m Anchen acquisition
This article was originally published in Scrip
Executive Summary
New Jersey-based Par Pharmaceutical has completed its $410 million acquisition of Anchen Pharmaceuticals, significantly expanding its pipeline and doubling its coverage of the oral extended release market.